| Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center |
NCT00546520: Effect of Inhaled Ciclesonide in Adult Patients With Asthma (BY9010/M1-125) |
|
|
| Completed | 3 | 21 | Europe | Ciclesonide | AstraZeneca | Asthma | 06/02 | 06/02 | | |
NCT00659750: To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402) |
|
|
| Completed | 3 | 418 | US | Ciclesonide, Placebo | AstraZeneca | Rhinitis, Allergic, Perennial | 05/04 | 04/05 | | |
NCT00270348: Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma |
|
|
| Completed | 3 | 450 | US | ciclesonide | Sanofi, Takeda | Asthma | | 09/04 | | |
NCT00163410: Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (4 to 15 y) (BY9010/M1-205) |
|
|
| Completed | 3 | 500 | RoW | Ciclesonide | AstraZeneca | Asthma | 12/04 | 12/04 | | |
NCT00659841: To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401) |
|
|
| Completed | 3 | 302 | US | Ciclesonide, Placebo | AstraZeneca | Rhinitis, Allergic, Seasonal, Hay Fever | 12/04 | 02/05 | | |
NCT00659594: Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406) |
|
|
| Completed | 3 | 500 | Canada | Ciclesonide, Placebo | AstraZeneca | Rhinitis, Allergic, Seasonal, Hay Fever | 02/05 | 09/05 | | |
NCT00163501: Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404) |
|
|
| Completed | 3 | 600 | US | Ciclesonide | AstraZeneca | Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever | 04/05 | 04/05 | | |
NCT00658918: To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405) |
|
|
| Completed | 3 | 120 | US | Ciclesonide nasal, Placebo | AstraZeneca | Rhinitis, Allergic, Perennial, Hay Fever | 04/05 | 11/05 | | |
NCT00659048: Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408) |
|
|
| Completed | 3 | 106 | US | Ciclesonide, Placebo | AstraZeneca | Rhinitis, Allergic, Perennial | 04/05 | 12/05 | | |
NCT00659503: Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407) |
|
|
| Completed | 3 | 420 | Canada | Ciclesonide, Placebo | AstraZeneca | Rhinitis, Allergic, Seasonal, Hay Fever | 04/05 | 11/05 | | |
NCT00163384: Effectiveness of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-136) |
|
|
| Completed | 3 | 240 | RoW | Ciclesonide | AstraZeneca | Asthma | 05/05 | 05/05 | | |
NCT00254956: Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent Asthma |
|
|
| Completed | 3 | 1568 | Europe | ciclesonide (XRP1526) | Sanofi, Takeda | Respiratory Tract Diseases, Respiratory Hypersensitivity, Asthma | 06/05 | 06/05 | | |
NCT00163397: Efficacy of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-137) |
|
|
| Completed | 3 | 120 | RoW | Ciclesonide | AstraZeneca | Asthma | 07/05 | 07/05 | | |
NCT00163514: Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403) |
|
|
| Completed | 3 | 636 | US, Canada | Ciclesonide | AstraZeneca | Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever | 07/05 | 07/05 | | |
NCT00163488: Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409) |
|
|
| Completed | 3 | 106 | US | Ciclesonide | AstraZeneca | Perennial Allergic Rhinitis, Allergic Rhinitis, Hay Fever | 08/05 | 08/05 | | |
NCT00163358: Efficacy of Ciclesonide vs Fixed Combination of Fluticasone Propionate/Salmeterol vs Placebo in Patients With Mild Persistent Asthma (12 to 75 y) (BY9010/M1-132) |
|
|
| Completed | 3 | 630 | Canada, Europe, RoW | Ciclesonide | AstraZeneca | Asthma | 10/05 | 10/05 | | |
NCT00163462 / 2004-000825-31: Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 y) (BY9010/M1-206) |
|
|
| Completed | 3 | 750 | Europe, RoW | Ciclesonide | AstraZeneca | Asthma | 11/05 | 11/05 | | |
NCT00163319: Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101) |
|
|
| Completed | 3 | 500 | Europe | Ciclesonide | AstraZeneca | Asthma | | 11/05 | | |
NCT00163371 / 2005-001386-34: Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010/M1-208) |
|
|
| Completed | 3 | 28 | Europe | Ciclesonide | AstraZeneca | Asthma | 12/05 | 12/05 | | |
NCT00163423 / 2004-001072-39: Efficacy of Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (12 to 75 y) (BY9010/M1-142) |
|
|
| Completed | 3 | 480 | Canada, Europe, RoW | Ciclesonide | AstraZeneca | Asthma | 01/06 | 01/06 | | |
NCT00163436 / 2005-002163-84: Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 y) (BY9010/M1-145) |
|
|
| Completed | 3 | 450 | Canada, Europe, RoW | Ciclesonide | AstraZeneca | Asthma | 01/06 | 01/06 | | |
NCT00174733: Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid |
|
|
| Completed | 3 | 456 | US | Ciclesonide (XRP1526) | Sanofi | Asthma | 02/06 | 02/06 | | |
NCT00163345: Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131) |
|
|
| Completed | 3 | 20 | Europe | Ciclesonide | AstraZeneca | Asthma | 05/06 | 05/06 | | |
NCT00261287: Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416) |
|
|
| Completed | 3 | 102 | US | Ciclesonide | AstraZeneca | Hay Fever, Perennial Allergic Rhinitis | 06/06 | 06/06 | | |
NCT00305487: Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417) |
|
|
| Completed | 3 | 660 | US | Ciclesonide nasal spray | AstraZeneca | Hay Fever, Seasonal Allergic Rhinitis | 10/06 | 10/06 | | |
| Completed | 3 | 1000 | Europe, RoW | Ciclesonide, Placebo | AstraZeneca | Asthma | 11/06 | 05/07 | | |
NCT00384475: A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413) |
|
|
| Completed | 3 | 500 | Canada | Ciclesonide Nasal Spray | AstraZeneca | Rhinitis, Allergic, Seasonal, Hay Fever | 01/07 | 01/07 | | |
NCT00174720: Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid. |
|
|
| Completed | 3 | 708 | US, Europe, RoW | Ciclesonide (XRP1526) | Sanofi | Asthma | 02/07 | 02/07 | | |
NCT00305461: Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101) |
|
|
| Completed | 3 | 101 | RoW | Ciclesonide | AstraZeneca | Asthma | 03/07 | 02/08 | | |
| Completed | 3 | 1080 | Europe, RoW | Ciclesonide, Placebo, Salbutamol | AstraZeneca, Nycomed GmbH | Asthma | 08/07 | 08/08 | | |
NCT00525772: Effect of Ciclesonide on Exercise Induced Bronchoconstriction |
|
|
| Completed | 3 | 26 | Canada | ciclesonide, ciclesonide (Alvesco) | Hamilton Health Sciences Corporation, Kolding Sygehus, Takeda | Asthma | 11/07 | 11/07 | | |
| Completed | 3 | 528 | US, Europe, RoW | Ciclesonide, Placebo | AstraZeneca | Asthma | 02/08 | 02/08 | | |
NCT00306163: Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101) |
|
|
| Completed | 3 | 37 | Europe | Ciclesonide, Fluticasone | AstraZeneca | Asthma | 08/08 | 09/08 | | |
NCT00790023: Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis |
|
|
| Completed | 3 | 707 | US | 80 mcg Ciclesonide, 160 mcg Ciclesonide, Placebo | Sunovion | Seasonal Allergic Rhinitis | 02/09 | 02/09 | | |
| Completed | 3 | 240 | Canada, Europe, RoW | Ciclesonide, Alvesco®, Placebo | AstraZeneca | Asthma | 06/09 | 04/10 | | |
NCT00953147: A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older |
|
|
| Completed | 3 | 1110 | US | Ciclesonide HFA 80 mcg, Ciclesonide HFA 160 mcg, Placebo | Sunovion | Allergic Rhinitis, Perennial Allergic Rhinitis | 01/10 | 05/10 | | |
NCT01010971: Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older |
|
|
| Completed | 3 | 671 | US | Ciclesonide HFA 160 μg, Ciclesonide HFA 80 μg, Placebo | Sunovion | Seasonal Allergic Rhinitis | 02/10 | 02/10 | | |
NCT01033825: Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis |
|
|
| Completed | 3 | 310 | US | Ciclesonide HFA Nasal Aerosol 320 mcg, Ciclesonide HFA Nasal Aerosol 160 mcg, HFA Nasal Aerosol placebo, Ciclesonide Aqueous Nasal Spray 200 mcg, Omnaris, AQ Nasal Spray Placebo, Placebo plus Dexamethasone HFA, Decadron, Placebo AQ plus Dexamethasone 6 mg | Sunovion | Perennial Allergic Rhinitis | 05/10 | 05/10 | | |
NCT01067105: A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older |
|
|
| Completed | 3 | 824 | US | ciclesonide HFA 160 μg | Sunovion | Perennial Allergic Rhinitis | 11/10 | 11/10 | | |
NCT01287364: Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis |
|
|
| Completed | 3 | 185 | US | ciclesonide hydrofluoroalkane (HFA) nasal aerosol, mometasone nasal inhalation, Nasonex® | Sunovion | Perennial Allergic Rhinitis | 04/11 | 04/11 | | |
NCT02273817: A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnarisâ„¢ Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis |
|
|
| Completed | 3 | 580 | US | Ciclesonide nasal spray, 50 μg per actuation. | Apotex Inc. | Seasonal Allergic Rhinitis | 08/11 | 08/11 | | |
NCT01378429: Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis |
|
|
| Completed | 3 | 89 | US | ciclesonide nasal aerosol, Placebo | Sunovion | Perennial Allergic Rhinitis, PAR | 11/11 | 11/11 | | |
NCT01401465: Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray |
|
|
| Completed | 3 | 327 | US | ciclesonide, mometasone | Sunovion | Perennial Allergic Rhinitis | 11/11 | 11/11 | | |
NCT01451541: A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR). |
|
|
| Completed | 3 | 848 | US | Ciclesonide nasal aerosol 37 mcg, ciclesonide nasal aerosol 74 mcg, Placebo | Sunovion | Perennial Allergic Rhinitis, PAR | 12/12 | 12/12 | | |
NCT01458275: A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR) |
|
|
| Completed | 3 | 847 | US | Ciclesonide nasal aerosol 37 mcg, ciclesonide nasal aerosol 74 mcg, Placebo | Sunovion | Seasonal Allergic Rhinitis | 03/13 | 03/13 | | |
VIDA, NCT01248065: Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma |
|
|
| Completed | 3 | 408 | US | Vitamin D3, Ciclesonide, Alvesco® | Milton S. Hershey Medical Center, National Heart, Lung, and Blood Institute (NHLBI) | Asthma | 01/14 | 01/14 | | |
| Completed | 3 | 520 | Europe, RoW | Ciclesonide | AstraZeneca | Bronchial Asthma | 08/14 | 08/14 | | |
NCT02155881: Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia |
|
|
| Completed | 3 | 80 | RoW | Ciclesonide, Omnaris®, Ciclesonide Placebo | AstraZeneca | Seasonal Allergic Rhinitis | 10/14 | 11/14 | | |
2006-001248-30: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 μg administered either in a once-daily in the morning regimen (160 μg qd AM) for 16 weeks or in a 160 μg qd AM regimen for 12 weeks preceded by a twice-daily regimen (80 μg bid) for 4 weeks, or in an 80 μg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids. |
|
|
| Completed | 3 | 25 | Europe | ciclesonide, ALVESCO, ALVESCO | Sanofi-Aventis U.S. Inc. | Asthma is a chronic inflammatory disease of the airways characterized by airway hyperresponsiveness, acute and chronic bronchoconstriction, airway edema, and mucus plugging. The inflammatory component of asthma is thought to involve many cell types including mast cells, eosinophils, T lymphocytes, neutrophils, and epithelial cells and their biologic products. Subjects with asthma most often present with symptoms of wheezing, shortness of breath, cough, and chest tightness. | | | | |
NCT02665806: Ciclesonide vs Fluticasone Nasal Sprays in Nasal Poplyposis |
|
|
| Unknown status | 3 | 32 | NA | Ciclesonide, Fluticasone | Tehran University of Medical Sciences | Chronic Rhinosinustis With Polyps | 02/16 | 03/16 | | |
2004-001681-40: Comparison of inhaled ciclesonide (640 µg/day) and fluticasone propionate (1000 µg/day) in patients with moderate and severe per-sistent asthma |
|
|
| Completed | 3 | 100 | Europe | Alvesco 160 Inhaler, Flixotide Evohaler CFC free 0,250mg, BY9010, ALVESCO 160 Inhaler, Flixotide Evohaler 250mcg, ALVESCO 160 Inhaler, Flixotide Evohaler 250mcg | ALTANA Pharma AG, ALTANA PHARMA | asthma | | 11/05 | | |
NCT00163332: Effect of Inhaled Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (18 to 65 y) (BY9010/M1-129) |
|
|
| Completed | 3 | 30 | Europe | Ciclesonide | AstraZeneca | Asthma | | | | |
NCT04377711: A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients |
|
|
| Completed | 3 | 400 | US | Ciclesonide, Alvesco, Placebo | Covis Pharma S.à.r.l. | COVID-19 | 01/21 | 01/21 | | |
NCT04435795: Inhaled Ciclesonide for Outpatients With COVID19 |
|
|
| Terminated | 2/3 | 215 | Canada | Normal Saline intranasal and placebo inhaler, Ciclesonide, Alvesco, Ciclesonide nasal, Omnaris | McGill University Health Centre/Research Institute of the McGill University Health Centre | COVID 19 | 06/21 | 07/21 | | |
COVERAGE, NCT04356495: Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation |
|
|
| Completed | 2/3 | 412 | Europe | Vitamins, Telmisartan, Ciclesonide, interferon β-1b | University Hospital, Bordeaux, University of Bordeaux | Corona Virus Infection, Sars-CoV2 | 10/21 | 10/21 | | |
| Recruiting | 2/3 | 5000 | Europe | Niclosamide, Placebo, Ciclesonide, Sotrovimab | Cambridge University Hospitals NHS Foundation Trust, Life Arc, Kidney Research UK (KRUK), UNION therapeutics, Addenbrookes Charitable Trust, GlaxoSmithKline, National Institute for Health Research, United Kingdom | Covid19 | 07/24 | 12/24 | | |
